Scarica l'app Stockscreener
51.52
2.59%
1.30
Dopo l'orario di chiusura:
52.01
0.49
+0.95%
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA - Zacks Investment Research
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Zacks Investment Research
Analysts Conflicted on These Healthcare Names: Quantum-Si (QSI), Crispr Therapeutics AG (CRSP) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
CRISPR Therapeutics AG (1CG.F) stock price, news, quote and history - Yahoo Finance UK
Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Climb 5.7%What's Next? - MarketBeat
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. - The Motley Fool
BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating - marketscreener.com
BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Counsel exercises options and sells 1,990 CRISPR Therapeutics (CRSP) shares under a trading plan. - Stock Titan
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 - GlobeNewswire
Trial data on a gene-editing treatment for very high triglycerides will be presented at a heart meeting. - Stock Titan
Form 144 CRISPR THERAPEUTICS AG For: 7 October By Investing.com - Investing.com Nigeria
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Officer James Kasinger proposes selling 1,990 shares of CRISPR Therapeutics (CRSP). - Stock Titan
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpHere's What Happened - MarketBeat
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy? - Yahoo! Finance Canada
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy? - Yahoo Finance
CRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026 - Quiver Quantitative
An experimental scleroderma treatment uses immune cells with changed genes. Early data will be presented Nov. 8. - stocktitan.net
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 - GlobeNewswire
CRISPR Therapeutics AG (CRSP) Stock forecasts - sg.finance.yahoo.com
Total common shares outstanding of CRISPR Therapeutics AG – HAN:1CG - TradingView
Pretax income of CRISPR Therapeutics AG – HAN:1CG - TradingView
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - finance.yahoo.com
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? - The Motley Fool
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? - finance.yahoo.com
CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com
One CRISPR treatment cut “bad” cholesterol in half for a full year - sciencedaily.com
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality - Investing.com
CRISPR Therapeutics' General Counsel James R. Kasinger Sells 10,400 Shares Following Option Exercise - Kalkine Media
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Nigeria
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com South Africa
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Canada
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan
CRISPR Therapeutics' Casgevy sales jump 78% in Q2, boosting long-term buy case despite AI gene editing risks - Pluang
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP) - Seeking Alpha
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme D - GuruFocus
0.90%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):